Chennai, 05 August 2025: Sanofi Consumer Healthcare India Limited (BSE:544250 I NSE: SANOFICONR) announced strong financial results for the second quarter of 2025. The company reported a 28% year-on-year increase in Q2 revenue to ₹2,209 million, supported by export operations and successful product launches. Thereby, sales growth stood at 27.5% from Q1 2025 and 27.6% YoY from 2024. Profit after tax (PAT) for the quarter reached ₹607 million, a 21% increase over Q1 2025.
Commenting on the results, Himanshu Bakshi, Managing Director, Sanofi Consumer Healthcare India Limited, said: “Our commitment to delivering high-quality, science-backed products continues to anchor our growth strategy—driven by a focused portfolio, research-led innovation, and an agile organization. This quarter reflects the outcomes of that focused approach, with successful relaunch of two previously recalled products and introduction of a new product. We also commenced export operations allowing us to extend our efforts towards international markets. As we look ahead, we remain steadfast in our purpose to make self-care simpler, more accessible and effective for consumers.”
During the half year, the company launched Allegra D*, a unique proposition in the Allergy segment, also relaunched Depura 60k and Combiflam Suspension* which were recalled voluntarily last year. Other legacy brands such as Avil*, and Depura continue to uphold strong consumer trust and drive long-term relevance in their respective categories.
Financial highlights
- Sale of Products
- Q2 2025: ₹2,209 million
- H1 2025: ₹3,935 million
- Profit After Tax
- Q2 2025: ₹606 million
- H1 2025: ₹1,107 million
